While many Covid-Companies have underperformed, Revive is trading at $0.47 as of June 30th 2021, an increase from the suggested entry price of $0.19 of 147% in less than 12 months. Revive is a unique company that is focused on psychedelic drugs for treatment of methamphetamine use disorder. Additionally, Revive uplisted from the OTC market to OTCQB as they were able to meet higher standards as a company. While the company is developing treatments for Gout and other diseases, in the short term, Bucillamine for the treatment of Covid is their only real pathway to significant revenues.
